Douglas Galasko on Aducanumab Still Needs to Prove Itself, Researchers Say
COMMENT I am a paid consultant for Biogen, so will not comment directly on the FDA’s deliberation of aducanumab. I raise here some general questions that may have an impact on AD therapeutics going forward as we are all taking stock of where we are with the data ...